Page 20 - Read Online

Page 14 of Ciardullo et al. Metab Target Organ Damage 2024;4:30 https://dx.doi.org/10.20517/mtod.2024.39

97. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin
sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10. DOI PubMed
98. Ciardullo S, Dodesini AR, Lepore G, et al. Development of a new model of insulin sensitivity in patients with type 2 diabetes and
association with mortality. J Clin Endocrinol Metab 2024;109:1308-17. DOI PubMed
99. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the
assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care
2000;23:57-63. DOI PubMed
100. Tohidi M, Arbab P, Ghasemi A. Assay-dependent variability of serum insulin concentrations: a comparison of eight assays. Scand J
Clin Lab Invest 2017;77:122-9. DOI PubMed
101. Guzder RN, Gatling W, Mullee MA, Byrne CD. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with
newly diagnosed type 2 diabetes. Diabetologia 2006;49:49-55. DOI PubMed
102. Shang Y, Grip ET, Modica A, et al. Metabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes.
Diabetes Care 2024;47:978-85. DOI PubMed PMC
103. Asghar A, Sheikh N. Role of immune cells in obesity induced low grade inflammation and insulin resistance. Cell Immunol
2017;315:18-26. DOI PubMed
104. Park H, Yoon EL, Kim M, Cho S, Nah EH, Jun DW. Nomenclature dilemma of metabolic associated fatty liver disease (MAFLD):
considerable proportions of mafld are metabolic healthy. Clin Gastroenterol Hepatol 2023;21:1041-1049.e3. DOI
105. Stefan N. Metabolically healthy and unhealthy normal weight and obesity. Endocrinol Metab (Seoul) 2020;35:487-93. DOI PubMed
PMC
106. Hrasko T, Bendlová B, Hainer V, Haluzík M. Metabolically healthy obese individuals - mechanisms and clinical relevance. Cesk
Fysiol 2016;65:38-46. PubMed
107. Calori G, Lattuada G, Piemonti L, et al. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian
individuals: the cremona study. Diabetes Care 2011;34:210-5. DOI PubMed PMC
108. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body
mass index categories: a systematic review and meta-analysis. JAMA 2013;309:71-82. DOI PubMed PMC
109. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous
coronary intervention: the obesity paradox? J Am Coll Cardiol 2002;39:578-84. DOI PubMed
110. Hainer V, Aldhoon-Hainerová I. Obesity paradox does exist. Diabetes Care 2013;36 Suppl 2:S276-81. DOI PubMed PMC
111. Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju ShN, et al. Body-mass index and all-cause mortality:
individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388:776-86. DOI PubMed
PMC
112. Blüher M. Metabolically healthy obesity. Endocr Rev 2020;41:bnaa004. DOI PubMed PMC
113. Mongraw-Chaffin M, Foster MC, Anderson CAM, et al. Metabolically healthy obesity, transition to metabolic syndrome, and
cardiovascular risk. J Am Coll Cardiol 2018;71:1857-65. DOI PubMed PMC
114. Singh A, Dhaliwal AS, Singh S, et al. Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a
representative us cohort. Dig Dis Sci 2020;65:978-86. DOI PubMed
115. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes
2001;50:1844-50. DOI PubMed